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Abstract 
Gilles de la Tourette Syndrome (TS) is a neurodevelopmental disorder characterized 
by a series of vocal and motor tics. It usually appears on childhood and affects 0.3-
0.9% of the population, with the incidence ratio of boys: girls being 4:1. TS has a 
complex pathogenic basis, including genetic, epigenetic and environmental factors. It 
shows great heritability, but the underlying genetic etiology remains unclear. The 
purpose of this study was the review of the most important recent genetic discoveries 
concerning TS. The research was conducted mainly through studies and scientific 
articles dating 2010 and after. Over the last few years, genetic research over TS has 
linked the disease with SNPs (single nucleotide polymorphisms) and CNVs (copy 
number variants) of specific genes, mainly involved in the dopaminergic and 
serotoninergic path. Many genes have been associated with the disease, including 
DRD2 and D4 (dopamine receptors D2 and D4), DAT1 (dopamine transporter 1), 
TPH2 (tryptophan hydroxylase), MAO-A (monoamine oxidase -Α), with more recent 
studies pointing towards NRXN1 (neurexin 1) and CNTN6 (contactin 6) genes. A 
mutation of a gene leading to insufficiency of histamine decarboxylase has been 
named as a risk factor for the syndrome. In other studies, CNVs in  AADAC 
(arylacetamide deacetylase) gene have also showed possible involvement in the onset 
and course of TS. Moreover, a recent genome-wide study associated an SNP in gene 
COL27A1 (collagen type ΧΧVΙΙ, alpha 1) with the disease. The recent genetic data in 
this field has led to the establishment of experimental genetically targeted therapies. 
Further scientific research over the genetics of TS is deemed necessary, as it can 
potentially lead to a personalized gene-targeted therapy to TS. 
 
Keywords: Tics, Genetics, Dopamine, Serotonin 
 
 
 
Corresponding author:  
Koulousi Alexandra, Laboratory of Medical Biology and Genetics, Medical School, 
Aristotle University of Thessaloniki, 54124, Thessaloniki, Greece. E-mail : 
akoulousi@gmail.com 
 
Aristotle Biomedical Journal, Vol 1, No 1 e-ISSN: 2653-9748 
 
2 
 
Abbreviations: 
TS: Tourette’s Syndrome 
ADHD: Attention deficit hyperactivity disorder 
OCD: Obsessive compulsive disorder 
CNVS: Copy number variants 
SNPS: Single nucleotide polymorphisms  
VNTRs: Variable number tandem repeats 
5-HT: Serotonin 
HDC: Histamine decarboxylase 
AADAC: Arylacetamide deacetylase 
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Introduction 
Gilles de la Tourette Syndrome or 
shortly Tourette Syndrome (TS) is a 
neurodevelopmental disorder that is 
characterized by a series of motor and 
vocal tics. It usually appears in 
childhood (mean age of onset is 6.4 
years) and improves in severity further 
on during the patient’s late adolescence 
or early adult life (Baldan et al, 2014; 
Hallett, 2015). 1/3 of TS patients seize 
having tics by early adulthood (Ünal 
and Akdemir, 2016). It affects 0.3- 
0.9% of the population (1 in every 
4,000-6,000 school-aged children), 
with male to female ratio being 4.4 to 1 
(Leckman, 2002; Hallett, 2015; Ünal 
and Akdemir, 2016; Paschou and 
Müller-Vahl, 2017). A family history 
is present in 51.7% of cases (Hallett, 
2015). Tourette syndrome presents 
with great phenotypical heterogeneity, 
with only 10–13.5% of pure TS cases, 
and is highly associated with other 
comorbid psychiatric diseases, and 
especially with attention-deficit 
hyperactivity disorder (ADHD, seen in 
55.6% of patients) and obsessive-
compulsive disorder (OCD, reported in 
45.9% of patients) (Hallett, 2015; 
Paschou and Müller-Vahl, 2017). 
These comorbid disorders are often 
associated with more distress and 
impairment than TS tics themselves 
(Fernandez, 2016). 
Tourette Syndrome is a complex 
disorder with great heterogeneity at its 
clinical manifestations that points 
towards a pathogenic basis consisting 
of both genetical and environmental 
factors. From the environmental 
factors, psychosocial stress remains the 
most important one influencing tic 
severity
 
(Hoekstra et al, 2013). 
Moreover, environmental exposures 
during the prenatal period, perinatal 
stages, and postnatal life, such as low 
birth weight and maternal smoking 
during pregnancy seem to affect the 
risk of both TS and comorbid ADHD 
/OCD. It has also been hypothesized 
that the onset of TS might arise as a 
result of autoimmune mechanisms 
following a group A β-hemolytic 
streptococcal infection, a condition 
known as pediatric autoimmune 
neuropsychiatric disorder associated 
with streptococcal infection 
(PANDAS). 
As far as the genetics are concerned, 
although family history is often 
positive, and a genetic etiology is 
assumed, no definitive TS-risk 
associated gene of major effect has yet 
been identified (Hallett, 2015; Paschou 
and Müller-Vahl, 2017). Lately many 
studies and worldwide collaborative 
projects have been trying to shed light 
on the genetics of TS and have 
managed to establish evidence for the 
first robust genetic associations 
concerning the disease. The aim of this 
study is to present a review of the 
literature regarding the genetic etiology 
of TS. 
 
Methods 
PubMed and Google Scholar were 
mainly used to obtain recent research 
papers and reviews (2010-2017).  The 
keywords used were as follows:  
Tourette Syndrome, genetics, tic 
disorders, neurobiology, 
pathophysiology and treatment.   
 
CLINICAL CHARACTERISTICS 
The tics characterizing TS are multiple, 
recurrent, motor movements and at 
least one vocalization (motor and 
phonic tics respectively), with onset 
before age 18 and persistence for over 
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a year (Fernandez, 2016). Phonic tics 
usually follow the appearance of motor 
tics by several years (Leckman, 2002). 
Tics can be varying from simple to 
complex. Simple motor tics include 
eye blinking or other facial 
movements, head or shoulder jerks or 
sudden movements of the arms or legs, 
while extreme clinical manifestations 
include self-injuring complex motor-
tics such as hitting or biting. Simple 
phonic tics include throat-clearing, 
flattening of the tongue, grunting, and 
sniffing.  Coprolalia (swearing tics) is 
reported at 10% of cases, while 
repetition of others’ phrases or words 
(echolalia) and repetition of one’s own 
words or phrases (palilalia) are also 
usual complex vocal tics. It should be 
noted that most patients report also a 
premonitory phenomenon, sometimes 
cited as “sensory tic”: a specific 
sensory feeling like “an urge” that 
usually precedes the tic; patients claim 
that they make the movement 
voluntarily to make the sensation go 
away (Hallett, 2015). 
 
RECENT GENETIC DATA  
Many twin and family studies have 
indicated TS as a non-mendelian 
heritable disorder with a population-
based heritability estimated at 0.77, a 
concordance of 77% in monozygotic 
twins and 23% in dizygotic twins 
(Ünal and Akdemir, 2016; Paschou and 
Müller-Vahl, 2017). First degree 
relatives of patients with TS have a 
high risk of developing TS or other 
tick disorders.  
This pattern of vertical transmission in 
family members suggests major gene 
effects (Leckman, 2002). 
Recently numerous molecular genetic 
studies of TS, examining cytogenetic 
abnormalities, copy number variants 
and rare mutations have been 
conducted; however only a few 
findings were able to be replicated in 
larger patient cohorts (Fernandez, 
2016; Hirschtritt et al, 2016). Genome-
wide association studies of common 
variants haven’t managed to generate 
statistically significant signals 
(Fernandez, 2016). 
TS is closely interwoven with two 
types of DNA polymorphisms 
(individual differences in a patient’s 
DNA): copy number variants (CNVs) 
and single nucleotide polymorphisms 
(SNPs)
 (Ünal and Akdemir, 2016). 
CNVs are genomic parts that consist of 
specific repeated large DNA sequences 
(200bp-2Mb) that vary in number 
among the population. In SNPs, 
usually 2 different nucleotides may 
appear in a single position of the 
human genome, thus creating different 
alleles per 1000 base pairs (Nussbaum, 
McInnes and Willard, 2017, p.230). 
There has also been association with 
specific variable number tandem 
repeats (VNTRs). VNTRs are 
polymorphisms that are characterized 
by the inlay of a varying number 
(ranging for hundreds to thousands) 
copies of a DNA sequence 10-100 bp 
wide.  
It seems most likely that risk for TS is 
configurated by numerous genes 
harboring small effect common 
variants and large effect rare variants, 
that come into effect by environmental 
and epigenetic influences (Fernandez, 
2016). 
Neurophysiological and brain imaging 
data reveal disruption of the cortico-
striato-thalamo-cortical (CSTC) 
circuits of the brain, as well as 
abnormalities in neurotransmitters such 
as dopamine, glutamate, serotonin, 
Aristotle Biomedical Journal, Vol 1, No 1 e-ISSN: 2653-9748 
 
5 
 
histamine and acetylcholine to be 
involved in the pathogenesis of TS 
(Felling and Singer, 2011; Paschou et 
al, 2013; Paschou and Müller-Vahl, 
2017). 
A series of studies were conducted 
concerning candidate genes related to 
these neurotransmitters and many of 
them indicated that neurotransmitter 
SNPs and CNVs are highly linked to 
TS, especially gene polymorphisms in 
the dopaminergic and serotonergic 
pathways (Paschou et al, 2013; Hallett, 
2015; Ünal and Akdemir, 2016).  
Concerning the dopaminergic pathway 
(Table 1), dopamine receptor 
D2 (DRD2) was initially associated 
with TS early in the 1990s (Paschou et 
al, 2013); a Taq1 A polymorphism 
(SNP rs1800497) in DRD2 and later 
three more SNPs in the same gene 
were reported (Ünal and Akdemir, 
2016).  In DRD4, a 48-bp VNTR has 
been associated with TS. Studies of 
the DRD1 and DRD3 genes have not 
shown any positive findings (Paschou 
et al, 2013). Furthermore, there have 
been indications of association 
between TS and the dopamine 
transporter DAT1 gene (SLC6A3); a 
10-repeat allele of a common 40-bp 
VNTR in the 3′ untranslated region of 
the DAT1 gene has been reported to be 
more frequent in TS patients (Paschou 
et al, 2013; Ünal and Akdemir, 2016). 
It should be noted that the 10-repeat 
DAT1 allele has also been suggested as 
a genetic risk factor for ADHD 
(Paschou et al, 2013). 
In the serotonergic pathway (Table 2), 
SNPs rs4565946 and rs4570625 of 
gene TPH2 have been associated with 
TS. TPH2 gene encodes the isozyme of 
tryptophan hydroxylase (rate-limiting 
enzyme in the synthesis of serotonin, 
or 5HT), found in the serotonergic 
neurons of the brain. As far as the 5HT 
receptor genes are concerned, very few 
genetic association studies have been 
conducted; only two polymorphisms in 
gene HTR2C (5HT receptor 2C) have 
been reported to have an association 
with the disorder. The SERT gene 
solute carrier family 6—
neurotransmitter transporter, serotonin, 
member 4 (SLC6A4) is implicated in 
OCD etiology. Although so far the 
results concerning its effect on TS have 
been inconclusive, high expression 
variants of SLC6A4 as well as a rare 
SLC6A4 gain-of-function variant 
(I425V) were significantly associated 
to TS. 
Monoamine oxidase-A gene (MAO-
A), which is involved in the 
deactivation of both dopaminergic and 
serotonergic pathways, has yielded 
many positive results in genetic 
association studies (Paschou et al, 
2013; Ünal and Akdemir, 2016). 
MAO-A has also been proposed as a 
susceptibility gene for ADHD 
(Paschou et al, 2013). 
Recent genetic work concerning TS 
has pointed towards the HDC 
(histamine decarboxylase) gene, a 
rather neglected neurotransmitter 
(Table 3). (Paschou et al, 2013; 
Baldan, 2014; Hallett, 2015; Ünal and 
Akdemir, 2016).
 
Specifically, it has 
been identified that a premature 
termination codon (W317X) forms at 
the gene due to a single rare coding 
mutation (Ünal and Akdemir, 2016). 
The HDC W317X mutation causes 
dysfunction in the HDC gene, which 
leads to overproduction of histamine, 
since the gene’s product, L-histidine 
decarboxylase, regulates histamine 
biosynthesis (Paschou et al, 2013). 
Another study established association 
between TS and two SNPs (rs854150 
Aristotle Biomedical Journal, Vol 1, No 1 e-ISSN: 2653-9748 
 
6 
 
Table 1: Genes associated with TS in the dopaminergic pathway 
Genes polymorphisms assosiated with ts 
GENES CODING receptors:  
   drd2 SNP rs1800497 
   drd4  48-bp VNTR 
   drd1, drd3 No positive findings 
OTHER genes:  
   GENE CODING dat1 10-repeat allele in a 40-bp VNTR 
  
Table 2: Genes associated with TS in the serotoninergic pathway 
genes polymorphisms assosiated with ts 
GENE CODING tph2 SNPs rs4565946, rs4570625 
htr2c (CODING 5ht receptor) Two polymorphisms, poor association 
(concerning all 5HT receptors) 
slc6a4 I425V (rare gain-of-function variant) 
Mostly implicated in OCD etiology 
GENE CODING MAO-A Various findings 
Involved in both dopaminergic and serotoninergic 
pathways 
Also associated with ADHD 
 
Τable 3: Other TS risk genes  
GENES POLYMORPHISMS ASSOSIATED 
WITH ts 
GENE CODING HDC W317X premature termination codon 
SNPs rs854150 and rs1894236 in 
indronic regions may be implicated in 
several neuropsychiatric disorders 
COL27A1 (9Q32 CHROMOSOME) SNP rs7868992 
polr3b SNP rs6539267 
gene coding aadac  Deletion CNV 
Other CNVs probably implicated 
genes coding nrxn1 and cntn6 20-fold and 10-fold (respectively) rare 
CNVs 
 
and rs1894236) within intronic regions 
of the HDC gene (Karagiannidis et al, 
2013). These findings established 
dysregulation of histaminergic 
neurotransmission as a rare cause of 
TS. The importance of histamine as a 
neurotransmitter and its role in several 
neuropsychiatric disorders are only 
recently starting to be appreciated. 
Lately, a recent large genome-wide  
 
association study identified an SNP 
(rs7868992) on chromosome 9q32 
within the gene COL27A1 (Hallett, 
2015). COL27A1 is a fibrillar 
collagen, but the function of COL27A1 
in the developing nervous system is 
unknown (Scharf et al, 2013). The 
same study identified a second SNP in 
its analysis, rs6539267, within an 
intron of POLR3B. This gene encodes 
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a major part of RNA polymerase III, 
which transcribes eukaryotic non-
coding RNAs (tRNAs, small rRNAs, 
microRNAs).  
Moreover, a study conducted by 
Thomas V. Fernandez (2016) revealed 
a statistically significant association of 
TS with a deletion CNV in AADAC 
(arylacetamide deacetylase) gene. The 
function of this gene in the brain 
remains obscure, but it seems that 
AADAC expression peaks in the 
striatum between birth and 
adolescence, which is accordant with 
the typical age of TS onset. This study 
followed an earlier study that had 
associated AADAC CNVs with TS but 
within a smaller group of subjects.  
More recently, an important 
collaborative study by Tourette 
Syndrome Association International 
Consortium for Genetics (TSAICG) 
has shown that rare CNVs increase the 
risk for TS (Huang et al, 2017). 
Specifically, NRXN1 (neurexin 1 
gene) and CNTN6 (contactin 6 gene) 
each conferred a substantially 
increased risk of TS: 20-fold and 10-
fold, respectively (Black, 2017). These 
are the first definitive TS risk genes 
that have been identified (Paschou and 
Müller-Vahl, 2017). Only 1% of TS 
cases carry one of these risk alleles in 
these two genes, which confirms the 
vast dispersion of the genetic risk for 
TS among numerous genes. NRXN1 
had been associated with TS again in 
the past, when 2 CNV studies indicated 
this gene’s involvement in the 
pathogenesis of TS, along with 
COL8A1(collagen, type VIII, alpha 1) 
and CTNNA3 (catenin, alpha 3) genes 
((Paschou et al, 2013; Ünal and 
Akdemir, 2016; Fernandez, 2016).  
Of course, these results point towards 
the need for further investigation on 
the cellular effects of these genes and 
perhaps related treatments.  
A wealth of studies has associated TS 
with variations spanning many other 
genes, but the meaning of this remains 
unclear. Such genes are, among others 
(Table 4):  
DBH gene, encoding dopamine beta-
hydroxylase, the enzyme which 
catalyzes the conversion of dopamine 
to norepinephrine (Paschou et al, 
2013), NLGN4 (neuroligin 4) gene and 
CNTNAP2 gene (contactin-associated 
protein-like 2—Caspr2), a member of 
the neurexin superfamily (Paschou et 
al, 2013; Ünal and Akdemir, 2016). 
Neurexins and neuroligins have a vital 
role in the development of synaptic 
connectivity and are main organizing 
molecules in excitatory glutamatergic 
and inhibitory GABAergic synapses 
(Paschou et al, 2013). The effect of 
these molecules in the pathogenesis of 
TS is also implied by the recent 
findings concerning NRXN1 gene and 
its association with TS that were 
mentioned earlier.  
gene of SAP90/PSD95-associated 
protein 3 (SAPAP3/DLGAP3), 
postsynaptic scaffolding protein highly 
expressed in striatal glutamatergic 
synapses, serotonin receptor (5-
HTR2A) and Androgen Receptor (AR) 
genes (O’Rourke et al, 2009), 
IMMP2L (inner mitochondrial 
membrane protein) gene, SLITRK1 
(SLIT family membrane protein, 1) 
gene, containing functional defects that 
were pointed out by cytogenetic 
studies
 (Ünal and Akdemir, 2016), 
DLGAP3 gene, encoding a 
postsynaptic scaffolding protein highly 
expressed in striatal glutamatergic 
synapses (Felling and Singer, 2011),  
FSCB (fibrous sheath cabyr-binding 
protein) gene (Fernandez, 2016).  
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Table 4: Other genes potentially implicated in TS 
COL8A1 AR 
CTNNA3 TPH2 
CNTNAP2 IMMP2L 
NLGN4 SLITRK1 
DBH DLGAP3 
SAP90/PSD95 FSCB 
5-HTR2A  
 
Although so far the research of TS 
mainly focuses on the genetic etiology 
of the disease, there are a few studies 
that have investigated the role of 
epigenetic factors and non-coding 
RNAs in the development of TS. One 
of these studies identified a nucleotide 
variant(var321) in the3′ UTR of the 
SLITRK1 gene (mentioned above), 
which leads to its stronger repression 
by miRNA-189 (Pagliaroli et al, 2016). 
Another study, the first Epigenome-
Wide Association Study (EWAS) with 
an aim of investigating DNA 
methylation differences between 
controls and patients, showed only 
small methylation differences between 
the two groups. Finally, IDH2 
(isocitrate dehydrogenase 2) and malic 
enzyme 1 genes, both of which seem to 
play a role in epigenetic modifications, 
have been associated with TS, thus 
potentially linking the disease with 
altered neural epigenetic patterns. 
Generally, it seems that environmental 
factors act via epigenetic modifications 
including modifications of the 
chromatin and regulatory non-coding 
RNAs, but further research in this area 
is required. 
 
 
Discussion 
It is apparent that further investigation 
of the role of variants in TS etiology 
will require the study of large sample 
sizes and collaborative efforts. 
Already, many large-scale 
collaborative projects have recently 
been established, aiming to elucidate 
the obscure genetic etiology of TS 
(Paschou and Müller-Vahl, 2017). 
Such projects are the Tourette 
Syndrome Association International 
Consortium for Genetics (TSAICG), 
the Tourette International 
Collaborative Genetics (TIC Genetics), 
the European Multicenter Tics in 
Children Study (EMTICS), TS-
EUROTRAIN (a Marie Curie Initial 
Training Network), the European 
Society for the Study of Tourette 
Syndrome (ESSTS) and the newly 
established ENIGMA-TS working 
group (Dietrich et al, 2015; Paschou 
and Müller-Vahl, 2017). These 
international collaborations use 
different approaches and work 
complementary, raising hopes for 
robust genetic discoveries concerning 
TS and related disorders over the next 
few years. 
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TREATMENT 
Until now, the usual first-line treatment 
for tics is behavioral/ psychological 
intervention (Black, 2017; Paschou and 
Müller-Vahl, 2017). The most common 
therapy of this kind is habit reversal 
therapy, which is based on the idea that 
tics are habits; patients are taught to 
recognize the “urge” and to try 
avoiding it by doing something more 
socially acceptable than the tic itself 
(Hallett, 2015). Pharmacological 
interventions are second-line options 
whereas some experimental 
approaches include deep brain 
stimulation (DBS) in the ventromedial 
thalamus; the latter is recommended 
only for severe and treatment 
refractory cases (Paschou and Müller-
Vahl, 2017). The most common 
pharmacologic approaches for TS are 
a2 agonists and atypical and typical 
neuroleptics (Leckman, 2002; 
Fernandez, 2016). A2 antagonists 
include clonidine and guanfacine 
(Hallett, 2015). Moreover, atypical 
antipsychotics are recommended as a 
second line treatment, especially 
risperidone and aripiprazole. Is seems 
that aripiprazole, a partial agonist at 
dopamine receptors, improves not only 
tics but also OCD and possibly other 
comorbid disorders such as depression, 
anxiety, and ADHD, but has no effect 
on premonitory urges. The 
development of new research strategies 
concerning the genetics of TS may 
hold the promise to identify definitive 
TS susceptibility genes and be the first 
step towards personalized gene-
targeted therapy in TS.  
 
Conclusion 
Tourette Syndrome is a disorder with a 
complex genetic background and an 
equally complex set of environmental 
and epigenetic risk factors. The efforts 
to unravel the genetic architecture of 
the disease started only a few decades 
ago but are moving vigorously towards 
new discoveries that will hopefully 
give ground for the development of 
genetically personalized therapies for 
patients with TS to ameliorate their 
quality of life. 
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